GlassScriptPhysician profile
Kelley Schwarte Baumhover
NPI 1104874643
$3,519.63
in general payments reported to CMS, 2019-2025
23 companies · $901 in 2025
The $901 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $185 · 2021: $480 · 2022: $489 · 2023: $637 · 2024: $616 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.19 | 2023-2025 | Lumigan, Alphagan P, Vuity |
| Mallinckrodt Hospital Products INC. | $466.52 | 2022-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $313.10 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $245.70 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $231.90 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $220.57 | 2019-2021 | |
| Alcon Vision LLC | $215.73 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Oyster Point Pharma, INC. | $174.88 | 2022-2025 | Tyrvaya, Ryzumvi |
| The Cameron-Ehlen Group, INC. | $139.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $123.96 | 2019-2023 | |
| Allergan, INC. | $105.53 | 2019-2021 | |
| Amgen INC. | $83.06 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $81.82 | 2023 | Tepezza |
| Sight Sciences, INC. | $52.86 | 2021-2024 | Omni Surgical System |
| Coopervision INC. | $52.14 | 2023 | Myday Contact Lens, Onefit Contact Lens |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $39.90 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $37.73 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $34.09 | 2023-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Thea Pharma INC. | $23.28 | 2022 | |
| Biotissue Holdings INC. | $23.04 | 2024 | |
| Kala Pharmaceuticals, INC. | $20.27 | 2021 | |
| Glaukos Corporation | $15.49 | 2021 | |
| Alimera Sciences, INC. | $13.16 | 2024 | Yutiq, Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Baumhover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.